Tofacitinib Cuts Inflammation in Down Syndrome, Cognitive Gains Unproven
A medication that quiets an overactive immune system cut inflammation in people with Down syndrome and improved painful skin conditions, a phase 2 trial published on 17 November 2026 found — but every participant got the drug, so the cognitive gains remain unproven.